The Valley Desk

ArticleCancer discoveryPublished

Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Thomas Jefferson University. Affiliation source

Publication record

Type
Article
Venue
Cancer discovery
Published
Subject terms
Humans; Prostate-Specific Antigen; Oxidoreductases; Antigens, Neoplasm; Treatment Outcome; Immunotherapy; Male; Prostatic Neoplasms, Castration-Resistant
PubMed ID
37861461
PubMed Central ID
PMC10784743
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal